** Shares of  drugmaker Scienture Holdings SCNX.O rise 10.34% to $0.4993 premarket

**  Co says it has expanded access to Arbli, its ready-to-use liquid losartan for high blood pressure

**  Losartan treats hypertension, a condition where consistently high blood pressure increases the risk of stroke and heart disease - SCNX

**  Co says Arbli now available at more than 2,500 healthcare sites, with coverage for 100 million insured Americans

** Expects continued Arbli prescription growth in Q1 and wider insurance and pharmacy coverage

** Says its nasal spray for opioid overdose emergencies, Rezenopy, is set for a U.S. launch in Q2 2026

** Shares fell ~92% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))